An engineered recombinase called Brec1 has been studied as a way to remove integrated HIV-1 DNA from infected cells. It is a different technology from CRISPR, and the evidence so far is experimental: cell and animal studies do not establish a cure in people. AIDS is the advanced clinical syndrome associated with HIV infection; the molecular target in these studies is HIV-1 proviral DNA, not “AIDS DNA.”
Why researchers are trying to remove HIV DNA
Combination antiretroviral therapy (ART) can suppress HIV reproduction, but viral DNA may remain integrated into the genomes of infected cells. These persistent copies, called proviruses, are part of the reason treatment generally has to continue. An excision strategy aims to remove the integrated viral sequence rather than simply block viral replication.
As an Amazon Associate I earn from qualifying purchases.
That goal is not the same as demonstrating that every infected cell has been reached, that all viral DNA has been removed, or that HIV cannot return. Those are demanding biological and clinical questions, not conclusions that follow from an editing result in a cell or animal.
What Brec1 is and how it works
Brec1 is an engineered recombinase: a protein designed to recognize a particular DNA sequence and rearrange DNA at that site. In a 2016 study, Karpinski and colleagues used 145 cycles of substrate-linked directed evolution to develop Brec1. The resulting enzyme recognized a 34-base-pair sequence in the long terminal repeats (LTRs) of many clinically relevant HIV-1 strains and subtypes.
#1 Best Overall
Because the target sequence occurs at the ends of the integrated viral genome, the proposed approach is to bring those ends together and excise the viral DNA between them. The study reported experiments in infected cells, with clinical isolates, and in humanized mice. These results demonstrate preclinical activity; they do not show that Brec1 has cured HIV in people.
How Brec1 differs from CRISPR
Brec1 and CRISPR-based approaches both aim to alter viral DNA, but they do not use the same molecular machinery. Brec1 is a recombinase selected to act at a defined sequence. CRISPR systems use a guide RNA to direct a nuclease, such as Cas9 or Cas12, to a DNA target, where the nuclease cuts the DNA. The cell’s repair processes then affect what happens at the cut site.
| Approach | Targeting and action | Evidence described here | Important qualification |
|---|---|---|---|
| Brec1 | An engineered recombinase recognizes a 34-base-pair HIV-1 LTR sequence and is intended to excise the intervening proviral DNA. | Cell, clinical-isolate, and humanized-mouse experiments reported in a 2016 study. | Not a CRISPR enzyme; no human cure is established by these experiments. |
| SaCas9 CRISPR | Guide RNAs direct the Cas9 nuclease to HIV DNA; cutting and subsequent repair can produce different outcomes. | A 2016 proof-of-concept study reported excision of a 978-base-pair fragment in transgenic mice after AAV9 delivery, and reduction of a targeted viral DNA segment in transgenic rats. | Animal-model findings are not evidence of efficacy in people, and outcomes depend on targeting and repair. |
| Cas12a delivery research | A separate research effort focuses on delivering Cas12a ribonucleoprotein or messenger RNA to CD4-expressing cells. | An NIH award record lists a project period from 1 December 2022 through 30 November 2027. | The award describes a research objective, not a clinically successful delivery system. |
These approaches have not been compared head-to-head in a clinical study in the evidence described here. A useful comparison therefore distinguishes the enzyme or nuclease, its target, the delivery method, the DNA outcome measured, and the stage of testing rather than treating “gene editing” as one interchangeable therapy.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →What has been tested in animals and people
Preclinical evidence
The Brec1 findings and the cited SaCas9 work are preclinical. A separate 2019 humanized-mouse study reported that sequential use of long-acting slow-effective-release ART (LASER ART) and CRISPR-Cas9 produced no detectable virus in several tested tissues in a subset of animals. In that experiment, neither treatment alone produced the same result. This is animal-model proof of concept, not evidence that the combination cures HIV in humans.
Clinical research is not the same as an approved treatment
A California Institute for Regenerative Medicine award record describes EBT-101 as an investigational, single-dose gene therapy using an AAV9 vector carrying HIV-specific CRISPR/Cas9 guide sequences. The listed study objectives include assessing safety, biodistribution, and excision. The award record is marked closed; it is a description of a clinical research program, not proof of efficacy or approval, and it does not establish current trial recruitment or status.
Thus, the evidence described here does not show that an engineered enzyme or gene-editing treatment has cured HIV in people. Brec1 is a preclinical research approach; EBT-101 is described in the cited award record as investigational. Neither should be presented as an approved HIV cure.
Rank #4
Why cutting out viral DNA is not the end of the problem
Excised DNA may remain biologically active
Removing a DNA segment from a chromosome does not necessarily make the excised DNA disappear immediately. A study of CRISPR/Cas9-mediated HIV DNA excision reported that excised proviral DNA could persist for weeks as circular molecules. Some circles had restored LTRs and could be transcriptionally active when the viral proteins Tat and Rev were present. The authors discuss limiting residual activity and reducing the possibility of reintegration.
Free tools Windows power users keep installed
One-click scans. No signup required.
Editing can produce more than clean excision
CRISPR outcomes can include mutations at a target site as well as the intended deletion. One dual-guide study found that target-site mutation occurred more often than fragment excision under the conditions tested, with outcomes varying by guide combination. Another publication reported large unintended deletions that could extend into surrounding cellular DNA after CRISPR-Cas attack on HIV proviral DNA. These are experimental safety concerns, not quantified estimates of risk to patients.
Best Value
Measurement affects what an experiment appears to show
A 2026 study of SaCas9 kinetics examined single- and dual-guide strategies and noted that PCR-based detection can favor amplification of shorter excision products over other outcomes. That means an apparent increase in excision products may not, by itself, describe the full mix of DNA repair outcomes. Assay design and measurement of residual or altered DNA matter when interpreting editing results.
Why delivery to reservoir cells is difficult
An editing system has to reach the infected cells that contain latent proviruses, not just cells that are easy to expose in a laboratory dish. The NIH-funded Cas12a project specifically describes work on delivery to CD4-expressing cells, underscoring that cell targeting is an active research problem. A vector or editing payload must reach the relevant cells, enter them, and act on the intended viral DNA while avoiding harmful effects elsewhere. The award description establishes that delivery is being studied; it does not establish that the challenge has been solved clinically.
What this means for people taking HIV treatment
Experimental excision research does not justify stopping or changing prescribed ART. The studies described here do not establish that all latent reservoir cells can be reached or that viral rebound is prevented in people. Anyone considering a treatment change should discuss it with their HIV clinician rather than act on preclinical findings or a research-program description.
Recommended Free Tools
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
